Vaccine Research
Vaccine Research
vacres
Medical Sciences
http://vacres.pasteur.ac.ir
1
admin
2383-2819
2423-4923
10.61186/vacres
en
jalali
1393
8
1
gregorian
2014
11
1
1
2
online
1
fulltext
en
Immune Response to Standard Hepatitis B Vaccination in HIV-Infected Patients
Original article
Original article
<span style="FONT-FAMILY: "Times New Roman",serif LETTER-SPACING: -0.1pt FONT-SIZE: 11pt mso-ascii-theme-font: major-bidi mso-fareast-font-family: Garamond mso-hansi-theme-font: major-bidi mso-bidi-theme-font: major-bidi mso-ansi-language: EN-US mso-fareast-language: EN-US mso-bidi-language: AR-SA"><strong>Background:</strong></span><span style="FONT-FAMILY: "Times New Roman",serif FONT-SIZE: 11pt mso-ascii-theme-font: major-bidi mso-fareast-font-family: Garamond mso-hansi-theme-font: major-bidi mso-bidi-theme-font: major-bidi mso-ansi-language: EN-US mso-fareast-language: EN-US mso-bidi-language: AR-SA"> Due to their similar routes of transmission, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) co-infection occurs considerably. HBV infection progresses more rapidly in HIV-infected patients. Therefore, HBV vaccination of all non-immune HIV infected patients is recommended. On the other hand, HIV-infected subjects have suboptimal responses to HBV vaccine. In this study, we aimed to determine the immune responses to standard HBV vaccination in HIV-infected patients. <font face="Times New Roman"><b style="mso-bidi-font-weight: normal"><span style="LETTER-SPACING: -0.1pt"><font size="3">Methods:</font></span></b> Fifty-six HIV infected patients who lacked evidence of either prior HBV infection or immunity were subjected to standard HBV vaccination, as 3 intramuscular injections of the standard dose (20 μg) of recombinant HBV vaccine at months 0, 1 and 6. Hepatitis B surface antibody (anti-HBs) titers were checked in all cases one month after the vaccination. A protective antibody response was defined as an anti-HBs titer of ≥10 IU/L.<b style="mso-bidi-font-weight: normal"><span style="LETTER-SPACING: -0.1pt"><font size="3"> R</font></span>esults: </b>HBV seroprotection was observed in 56.6% of HIV-infected patients. There was no significant difference between cases with and without seroprotection regarding age, sex, possible route of HIV acquisition, CD4 count, receiving antiretroviral therapy (and its duration) and HCV infection.<b style="mso-bidi-font-weight: normal"> Conclusion: </b>Our study confirms previous reports that HIV-infected patients have a lower response rate to the standard HBV vaccination compared to general population. So other strategies are needed to improve the HBV vaccine response rate in HIV cases.</font></span>
Human Immunodeficiency Virus(HIV), Hepatitis B Virus(HBV), Vaccination.
12
15
http://vacres.pasteur.ac.ir/browse.php?a_code=A-10-27-12&slc_lang=en&sid=1
Amitis
Ramezani